Use of moxifloxacin in tuberculosis regimen in a french teaching hospital;Bilan de l'utilisation de la moxifloxacine dans le traitement de la tuberculose dans un hôpital universitaire

Medecine et Maladies Infectieuses

Volumn 40, Issue 10, 2010, Pages 568-573

  Berdot, S ^a,b   Papy, E ^a   Rioux, C ^a   Diamantis, S ^a   Ruimy, R ^a   Dombret, M C ^a   Arnaud, P ^a   Bouvet, E ^a  

^a BICHAT HOSPITAL   (France)

^b FACULTÉ DES SCIENCES PHARMACEUTIQUES ET BIOLOGIQUES   (France)

Author keywords

Antitubercular agents; Moxifloxacin; Mycobacterium tuberculosis; Retrospective studies; Tuberculosis

Indexed keywords

ISONIAZID; MOXIFLOXACIN; RIFAMPICIN;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; CLINICAL ARTICLE; DRUG INTERACTION; EXTRAPULMONARY TUBERCULOSIS; FEMALE; FRANCE; HUMAN; LUNG TUBERCULOSIS; MALE; MILIARY TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; PRESCRIPTION; RECURRENT DISEASE; RETROSPECTIVE STUDY; TEACHING HOSPITAL; TREATMENT FAILURE; TUBERCULOSIS;

ADULT; AGED; ANTITUBERCULAR AGENTS; AZA COMPOUNDS; COMORBIDITY; DRUG PRESCRIPTIONS; DRUG THERAPY, COMBINATION; DRUG UTILIZATION; FEMALE; FRANCE; HIV INFECTIONS; HOSPITALS, UNIVERSITY; HUMANS; MALE; MIDDLE AGED; QUINOLINES; RECURRENCE; RETROSPECTIVE STUDIES; TUBERCULOSIS; YOUNG ADULT;

EID: 77958501443     PISSN: 0399077X     EISSN: 17696690     Source Type: Journal    
DOI: 10.1016/j.medmal.2010.04.004     Document Type: Article

References (30)

1. Les cas de tuberculose maladie déclarés en France en 2007. Bulletin épidémiologique hebdomadaire, 2009. (consulté le 15 septembre, 2009, sur ). http://www.invs.sante.fr/beh/2009/12_13/beh_12_13_2009.pdf.
2. Surveillance de la résistance aux antituberculeux en France: données récentes. Bulletin épidémiologique hebdomadaire, 2007. (consulté le 15 septembre, 2009, sur ). http://www.invs.sante.fr/beh/2007/11/beh_11_2007.pdf.
3. Dautzenberg B., Frechet-Jachym M., Maffre J.P., Cardot E., Grignet J.P. When should standard treatment not be applied for the tuberculosis patient?. Rev Mal Respir 2004, 21:S75-97.
4. Blumberg H.M., Burman W.J., Chaisson R.E., et al. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America: treatment of tuberculosis. Am J Respir Crit Care Med 2003, 167:603-662.
5. Goble M., Iseman M.D., Madsen L.A., Waite D., Ackerson L., Horsburgh C.R. Treatment of 171 patients with pulmonary tuberculosis resistant to isoniazid and rifampin. N Engl J Med 1993, 328:527-532.
6. Telzak E.E., Sepkowitz K., Alpert P., et al. Multidrug-resistant tuberculosis in patients without HIV infection. N Engl J Med 1995, 333:907-911.
7. Gillespie S.H., Billington O. Activity of moxifloxacin against mycobacteria. J Antimicrob Chemother 1999, 44:393-395.
8. Rodriguez J.C., Ruiz M., Lopez M., Royo G. In vitro activity of moxifloxacin, levofloxacin, gatifloxacin and linezolid against Mycobacterium tuberculosis. Int J Antimicrob Agents 2002, 20:464-467.
9. Tortoli E., Dionisio D., Fabbri C. Evaluation of moxifloxacin activity in vitro against Mycobacterium tuberculosis, including resistant and multidrug-resistant strains. J Chemother 2004, 16:334-336.
10. Codecasa L.R., Ferrara G., Ferrarese M., et al. Long-term moxifloxacin in complicated tuberculosis patients with adverse reactions or resistance to first line drugs. Respir Med 2006, 100:1566-1572.
11. Nuermberger E.L., Yoshimatsu T., Tyagi S., et al. Moxifloxacin-containing regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004, 169:421-426.
12. Veziris N., Truffot-Pernot C., Aubry A., Jarlier V., Lounis N. Fluoroquinolone-containing third-line regimen against Mycobacterium tuberculosis in vivo. Antimicrob Agents Chemother 2003, 47:3117-3122.
13. Pletz M.W., De Roux A., Roth A., Neumann K.H., Mauch H., Lode H. Early bactericidal activity of moxifloxacin in treatment of pulmonary tuberculosis: a prospective, randomized study. Antimicrob Agents Chemother 2004, 48:780-782.
14. Burman W.J., Goldberg S., Johnson J.L., et al. Moxifloxacin versus ethambutol in the first 2 months of treatment for pulmonary tuberculosis. Am J Respir Crit Care Med 2006, 174:331-338.
15. Conde M.B., Efron A., Loredo C., et al. Moxifloxacin versus ethambutol in the initial treatment of tuberculosis: a double-blind, randomised, controlled phase II trial. Lancet 2009, 373:1183-1189.
16. Dorman S.E., Johnson J.L., Goldberg S., et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009, 180:273-280.
17. Bonora S., Mondo A., Trentini L., Calcagno A., Lucchini A., Di Perri G. Moxifloxacin for the treatment of HIV-associated tuberculosis in patients with contra-indications or intolerance to rifamycins. J Infect 2008, 57:78-81.
18. Ball P., Stahlmann R., Kubin R., Choudhri S., Owens R. Safety profile of oral and intravenous moxifloxacin: cumulative data from clinical trials and postmarketing studies. Clin Ther 2004, 26:940-950.
19. Valerio G., Bracciale P., Manisco V., Quitadamo M., Legari G., Bellanova S. Long-term tolerance and effectiveness of moxifloxacin therapy for tuberculosis: preliminary results. J Chemother 2003, 15:66-70.
20. Veyssier P., Voirot P., Begaud B., Funck-Brentano C. Cardiac tolerance of moxifloxacin: clinical experience from a large observational French study in usual medical practice (Immediat study). Med Mal Infect 2006, 36:505-512.
21. Ho C.C., Chen Y.C., Hu F.C., Yu C.J., Yang P.C., Luh K.T. Safety of fluoroquinolone use in patients with hepatotoxicity induced by antituberculosis regimens. Clin Infect Dis 2009, 48:1526-1533.
22. European medicines agency recommends restricting the use of oral moxifloxacin-containing medicines. European Medicines Agency, 2008. (consulté le 20 septembre, 2008, sur ). http://www.ema.europa.eu/pdfs/human/press/pr/38292708en.pdf.
23. Information importante de pharmacovigilance. Moxifloxacine. Afssaps, 2008. (consulté le 20 octobre, 2008, sur ). http://www.afssaps.fr/Infos-de-securite/Lettres-aux-professionnels-de-sante/Information-importante-de-pharmacovigilance-concernant-IZILOX-Bayer-Sante.
24. Point d'information sur Izilox® (moxifloxacine). Modification des conditions d'utilisation. Afssaps, 2008. (consulté le 20 octobre, 2008, sur ). http://www.afssaps.fr/Infos-de-securite/Communiques-de-presse/Izilox-R-moxifloxacine-modification-des-conditions-d-utilisation.
25. Drug safety update. Latest advice for all medicines users. Medicines and healthcare products regulatory agency and commission on human medicines, 2008. (consulté le 20 octobre, 2008, sur ). http://www.mhra.gov.uk/Publications/Safetyguidance/DrugSafetyUpdate/CON023078.
26. Nijland H.M., Ruslami R., Suroto A.J., et al. Rifampicin reduces plasma concentrations of moxifloxacin in patients with tuberculosis. Clin Infect Dis 2007, 45:1001-1007.
27. Weiner M., Burman W., Luo C.C., et al. Effects of rifampin and multidrug resistance gene polymorphism on concentrations of moxifloxacin. Antimicrob Agents Chemother 2007, 51:2861-2866.
28. Synthèse et recommandations du groupe de travail du Conseil Supérieur d'Hygiène Publique de France (2002-2003). Traitement de la tuberculose-maladie. Rev Mal Respir 2003;20:S45-51.
29. Guide-Affection de longue durée. Tuberculose active. Haute Autorité de santé, 2007. (consulté le 20 octobre, 2008, sur ). http://www.has-sante.fr/portail/upload/docs/application/pdf/07-029_tuberculose-guide_edite_sans_lap.pdf.
30. Drlica K., Zhao X., Kreiswirth B. Minimising moxifloxacin resistance with tuberculosis. Lancet Infect Dis 2008, 8:273-275.